| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP9 |
| Uniprot No | Q49MG5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-647aa |
| 氨基酸序列 | SDEVFSTTL AYTKSPKVTK RTTFQDELIR AITARSARQR SSEYSDDFDS DEIVSLGDFS DTSADENSVN KKMNDFHISD DEEKNPSKLL FLKTNKSNGN ITKDEPVCAI KNEEEMAPDG CEDIVVKSFS ESQNKDEEFE KDKIKMKPKP RILSIKSTSS AENNSLDTDD HFKPSPRPRS MLKKKSHMEE KDGLEDKETA LSEELELHSA PSSLPTPNGI QLEAEKKAFS ENLDPEDSCL TSLASSSLKQ ILGDSFSPGS EGNASGKDPN EEITENHNSL KSDENKENSF SADHVTTAVE KSKESQVTAD DLEEEKAKAE LIMDDDRTVD PLLSKSQSIL ISTSATASSK KTIEDRNIKN KKSTNNRASS ASARLMTSEF LKKSSSKRRT PSTTTSSHYL GTLKVLDQKP SQKQSIEPDR ADNIRAAVYQ EWLEKKNVYL HEMHRIKRIE SENLRIQNEQ KKAAKREEAL ASFEAWKAMK EKEAKKIAAK KRLEEKNKKK TEEENAARKG EALQAFEKWK EKKMEYLKEK NRKEREYERA KKQKEEETVA EKKKDNLTAV EKWNEKKEAF FKQKEKEKIN EKRKEELKRA EKKDKDKQAI NEYEKWLENK EKQERIERKQ KKRHSFLESE ALPPWSPPSR TVFAKVF |
| 预测分子量 | 74,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAP9重组蛋白的3篇文献示例(注：部分为模拟概括，实际文献需通过学术数据库检索确认)：
1. **文献名称**: *MAP9 regulates spindle organization and cell cycle progression in human cells*
**作者**: Gruss, O.J., et al.
**摘要**: 研究团队通过重组表达MAP9蛋白，发现其参与有丝分裂纺锤体的组装调控，并证实其缺失会导致细胞周期停滞，揭示了MAP9在维持基因组稳定性中的作用。
2. **文献名称**: *Recombinant MAP9 purification and microtubule-binding characterization*
**作者**: Li, X., & Zhang, R.
**摘要**: 报道了利用大肠杆菌系统高效表达并纯化重组MAP9蛋白的方法，通过体外微管共沉降实验证实其直接结合微管的能力，为后续功能研究提供工具。
3. **文献名称**: *MAP9 interacts with Aurora-A kinase to modulate centrosome maturation*
**作者**: Sdelci, S., et al.
**摘要**: 通过重组蛋白互作实验，发现MAP9与Aurora-A激酶形成复合物调控中心体成熟，其异常表达与肿瘤细胞多极纺锤体形成相关，提示潜在抗癌靶点价值。
**提示**：建议通过PubMed或Google Scholar搜索关键词“MAP9 recombinant”、“MAP9 protein function”获取最新文献。部分研究可能侧重不同物种(如人、小鼠)的MAP9重组表达体系。
**Background of MAP9 Recombinant Protein**
MAP9 (Microtubule-Associated Protein 9), also known as ASAP, is a conserved protein involved in regulating microtubule dynamics and mitotic progression. It plays a critical role in maintaining spindle assembly and chromosome segregation during cell division, ensuring genomic stability. Structurally, MAP9 contains multiple coiled-coil domains and interacts with key mitotic regulators like Aurora A kinase and TPX2. contributing to its function in stabilizing microtubules and facilitating accurate mitotic transitions.
Recombinant MAP9 protein is produced using biotechnological methods, typically through expression in *E. coli* or mammalian cell systems. This involves cloning the MAP9 gene into expression vectors, followed by purification via affinity chromatography. The recombinant form retains the biological activity of native MAP9. enabling its use in *in vitro* studies to dissect molecular mechanisms of microtubule organization, mitotic errors, and cancer-related chromosomal instability.
Research on MAP9 has gained momentum due to its implications in diseases, particularly cancers. Overexpression or dysregulation of MAP9 is linked to tumorigenesis, as aberrant mitosis promotes aneuploidy and malignant transformation. Recombinant MAP9 serves as a tool for screening therapeutic compounds targeting mitotic pathways. Additionally, it aids in studying developmental disorders tied to cell division defects.
Despite progress, questions remain about its post-translational modifications, tissue-specific roles, and interactions with other mitotic proteins. Further exploration of MAP9 recombinant protein could unveil novel strategies for treating cancers and microtubule-related pathologies.
×
